Lv62
1846 积分 2021-05-31 加入
Systemic Treatments for Chronic Spontaneous Urticaria: Anti-IgE and Beyond
1个月前
已关闭
Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with Efficacy in Liquid and Solid Tumor Models
1个月前
已完结
Discovery of Novel Class of METTL3 Inhibitors with a Pyridin-2(1 H )-one Moiety
1个月前
已完结
siRNA: Mechanism of action, challenges, and therapeutic approaches
1个月前
已完结
N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective
1个月前
已完结
siRNA-based delivery systems: Technologies, carriers, applications, and approved products
1个月前
已完结
Recent advances in optimizing siRNA delivery to hepatocellular carcinoma cells
1个月前
已完结
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
2个月前
已完结
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial
2个月前
已完结
Emerging IgE and non-IgE targeted therapies for chronic urticaria
3个月前
已完结
皖公网安备34019202002308
